Pulmonary Arterial Hypertension
Conditions
Keywords
Diagnostic Techniques and Procedures
Brief summary
This is an open label phase 2 pilot study designed to evaluate the safety, tolerability and device performance of the GeNO nitrosyl delivery system during right heart catheterization (RHC) in participants with pulmonary arterial hypertension (PAH). All participants will receive inhaled nitric oxide in oxygen or nitric oxide in air delivered by nasal cannula. Hemodynamics, clinical laboratory and clinical assessment data will be collected on all participants to evaluate safety.
Detailed description
TREATMENT/FOLLOW-UP: Participants meeting eligibility criteria will receive open label nitric oxide at 80 ppm via a nasal cannula. Hemodynamic clinical laboratory and clinical assessment data will be collected at baseline, after 15 minutes of inhaled nitric oxide administration, post RHC procedure and at hospital discharge. Day 5 +/- 3 post RHC, telephone contact to assess general health status.
Interventions
DRUGNitric Oxide generated by the GeNO nitrosyl delivery system
single short-term exposure to inhaled nitric oxide using the GeNO nitrosyl delivery system.
Sponsors
Geno LLC
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Have a confirmed diagnosis of PAH, WHO Group 1. * WHO Functional Class II or III equivalent, PAH. * Have been clinically stable with regard to signs and symptoms of PAH for at least 30 days prior to RHC. * May be receiving approved mono therapies or combination PAH therapies. * Females that are surgically sterile or post-menopausal. Females of chil-bearing potential must have negative pregnancy test and must be practicing adequate birth control.
Exclusion criteria
* Have had a new type of chronic therapy (including but not limited to oxygen, a different category of vasodilator, a diuretic, digoxin) for PAH added within (1) month of RHC. * Have any PAH medication except for anticoagulants discontinued within the week prior to RHC. * Have evidence of significant parenchymal lung disease as evidenced by pulmonary function tests within the last six months * CREST (calcinosis, Raynaud phenomenon, esophageal dysmotility, sclerodactyly, telangiectasia) syndrome * Have a history of uncontrolled sleep apnea within three months of RHC. * Have a history of hemodynamically significant left-sided heart disease * Have evidence of left-sided heart disease * Have any other disease that is associated with pulmonary hypertension (e.g. congenital systemic-to-pulmonary shunt, sickle cell anemia, schistosomiasis). * Documented uncontrolled systemic hypertension as evidenced by systolic blood pressure greater than 160 mmHg or diastolic blood pressure greater than 100 mmHg. * Have used prescription appetite suppressants within 3 months prior to wean/transition. * Have chronic kidney disease stage IV or worse or the requirement for dialysis. * Be receiving an investigational drug, have in place an investigational device, or have participated in an investigational drug study within the past 30 days. * Have had an atrial septostomy. * Have anemia (hemoglobin \<10 g/dL), active infection or any other ongoing condition that would interfere with the interpretation of study assessments. * Have any serious or life-threatening disease other than conditions associated with PAH (e.g. malignancy requiring aggressive chemotherapy, renal dialysis, etc.). * Have unstable psychiatric status or be mentally incapable of understanding the objectives, nature or consequences of the trial * Participant is pregnant or lactating * Significant, ongoing alcohol or drug abuse.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence and Severity of Treatment Emergent Adverse Events; Unanticipated Adverse Device Effects and Changes From Baseline to End-of-study in Clinical Lab Parameters and Vital Signs. | through Day 30 Follow-up Period | Adverse Event Severity \[through Day 30 Follow-Up Period\] Unanticipated Device Effects: any system malfunction, damage or NO2 threshold monitor alarms \[through discharge from Treatment Period\] Laboratory Tests: Hematology (CBC with differential), Chemistry (glucose, BUN, creatinine, sodium, potassium, carbon dioxide, creatinine kinase), Activated Clotting Test or Prothrombin Time, arterial blood gas, and methemoglobin. \[through discharge from Treatment Period\] Vital Signs: pulse, blood pressure, respiratory rate \[through discharge from Treatment Period\] |
| Adequacy of Device Design and Suitability of the Instructions for Use by the Clinician Using a Device Performance Evaluation | through Treatment Period | — |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Nitric Oxide Via GeNO Nitrosyl System Nitric Oxide via GeNO Nitrosyl System | 10 |
| Total | 10 |
Baseline characteristics
| Characteristic | Nitric Oxide Via GeNO Nitrosyl System |
|---|---|
| Age, Categorical <=18 years | 0 Participants |
| Age, Categorical >=65 years | 1 Participants |
| Age, Categorical Between 18 and 65 years | 9 Participants |
| Age Continuous | 51 years STANDARD_DEVIATION 15.17 |
| Region of Enrollment United States | 10 participants |
| Sex: Female, Male Female | 8 Participants |
| Sex: Female, Male Male | 2 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | — / — |
| other Total, other adverse events | 0 / 0 |
| serious Total, serious adverse events | 0 / 0 |
Outcome results
Primary
Adequacy of Device Design and Suitability of the Instructions for Use by the Clinician Using a Device Performance Evaluation
Time frame: through Treatment Period
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Nitric Oxide Via GeNO Nitrosyl System | Adequacy of Device Design and Suitability of the Instructions for Use by the Clinician Using a Device Performance Evaluation | 10 participants |
Primary
Incidence and Severity of Treatment Emergent Adverse Events; Unanticipated Adverse Device Effects and Changes From Baseline to End-of-study in Clinical Lab Parameters and Vital Signs.
Adverse Event Severity \[through Day 30 Follow-Up Period\] Unanticipated Device Effects: any system malfunction, damage or NO2 threshold monitor alarms \[through discharge from Treatment Period\] Laboratory Tests: Hematology (CBC with differential), Chemistry (glucose, BUN, creatinine, sodium, potassium, carbon dioxide, creatinine kinase), Activated Clotting Test or Prothrombin Time, arterial blood gas, and methemoglobin. \[through discharge from Treatment Period\] Vital Signs: pulse, blood pressure, respiratory rate \[through discharge from Treatment Period\]
Time frame: through Day 30 Follow-up Period
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Nitric Oxide Via GeNO Nitrosyl System | Incidence and Severity of Treatment Emergent Adverse Events; Unanticipated Adverse Device Effects and Changes From Baseline to End-of-study in Clinical Lab Parameters and Vital Signs. | 0 participants |